Clinical trialObsRecruiting
Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia
Spatial Multi-omics Mechanism Analysis and Multimodal Intelligent Early Warning of Cachexia in Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Recruiting
- Study type
- Observational
- Start
- 24 April 2026
- Expected end
- 31 August 2028
- Enrollment
- 500 participants
- Sites
- 1
- Primary outcomes
- Overall Survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 26 June 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The goal of this observational study is to explore the spatial multi-omics mechanism of cachexia in pancreatic cancer and construct a high-precision multimodal intelligent early warning model for its early diagnosis in pathologically confirmed pancreatic ductal adenocarcinoma patients aged ≥18 years with an expected survival of ≥1 month. The main questions it aims to answer are: 1) Can spatial transcriptomics/metabolomics reveal the interaction mechanism between tumor microenvironment and metabolism in pancreatic cancer cachexia? 2)Can a multimodal AI early warning model be built to achieve accurate early identification of pancreatic cancer cachexia? Researchers will compare the surgical cohort and advanced cohort to see the differences in cachexia incidence and progression rules among different subgroups. Participants will complete baseline questionnaires on physical and mental state, nutrition and muscle strength, undergo imaging examinations and provide biological samples (blood, feces, tissue etc.), and receive regular follow-ups for updated questionnaires, imaging rechecks and supplementary biological sample collection until death, loss to follow-up or voluntary withdrawal.
Arm public domain (ClinicalTrials.gov)
Resectable group (): Patients is resectable and received surgery
Arm public domain (ClinicalTrials.gov)
Unresectable group (): Patients is unresectable
Primary outcome public domain (ClinicalTrials.gov)
Overall Survival. Time frame: Time from enrollment to all-cause death, assessed up to 3 years..
Secondary outcome public domain (ClinicalTrials.gov)
Cachexia-free survival. Time frame: Time from enrollment to cachexia diagnosis, assessed up to 3 years..
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: * Patients with pathologically confirmed pancreatic ductal adenocarcinoma. * Aged ≥18 years with an expected survival time of ≥1 month (to be assessed for the advanced cohort). Assessment criteria: Comprehensive evaluation based on the patient's radiological tumor burden, vital organ function and physical status. Specific quantitative indicators: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, or Karnofsky Performance Status (KPS) score of ≥60. For patients in the advanced cohort, the assessment shall be jointly confirmed by two attending physicians with the professional title of associate chief physician or above in combination with radiological examination results. * Voluntarily sign the informed consent form. Exclusion Criteria: * Complicated with other untreated malignant tumors or severe mental disorders. * Pregnant women or patients unable to cooperate with follow-up.
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 500 participants (estimated).